Rockwell Medical, Inc. operates within the specialized hemodialysis concentrates market where patient safety and product reliability are paramount. Despite its critical role, the company endured a marked revenue decline and swung to operating losses in 2025 as its largest customer, DaVita, significantly reduced purchases. Concurrently, competitive pressure from larger, vertically integrated firms limited pricing power while capital constraints imposed by debt covenants restricted strategic flexibility. Rockwell’s efforts to rationalize operations through facility closures and efficiency upgrades partially mitigated margin pressures but did not prevent negative cash flow or net losses for the year.